Cyrus Harmon Sells 15,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 15,000 shares of the firm’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $9.51, for a total value of $142,650.00. Following the completion of the sale, the director now owns 811,283 shares of the company’s stock, valued at $7,715,301.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Cyrus Harmon also recently made the following trade(s):

• On Thursday, March 28th, Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $10.97, for a total transaction of $219,400.00.
• On Thursday, February 29th, Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $12.41, for a total transaction of $310,250.00.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ OLMA traded down $0.33 during midday trading on Thursday, hitting $10.07. The stock had a trading volume of 968,451 shares, compared to its average volume of 782,611. The company’s 50-day simple moving average is $11.61 and its 200 day simple moving average is $12.83. The firm has a market cap of $563.22 million, a P/E ratio of -4.61 and a beta of 2.10. Olema Pharmaceuticals, Inc. has a fifty-two week low of $5.02 and a fifty-two week high of $17.79.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings results on Monday, March 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.49). Equities analysts expect that Olema Pharmaceuticals, Inc. will post -2.34 EPS for the current fiscal year.

Analysts Set New Price Targets

OLMA has been the topic of several research analyst reports. Capital One Financial reissued an “overweight” rating on shares of Olema Pharmaceuticals in a research note on Thursday, February 22nd. Citigroup initiated coverage on Olema Pharmaceuticals in a report on Tuesday, January 30th. They set a “buy” rating and a $20.00 price objective on the stock. Finally, The Goldman Sachs Group initiated coverage on Olema Pharmaceuticals in a research note on Tuesday, April 2nd. They issued a “buy” rating and a $24.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Olema Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $21.43.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio bought a new position in Olema Pharmaceuticals during the third quarter worth about $35,000. China Universal Asset Management Co. Ltd. bought a new position in Olema Pharmaceuticals during the fourth quarter worth about $89,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Olema Pharmaceuticals during the fourth quarter worth about $130,000. SG Americas Securities LLC bought a new position in Olema Pharmaceuticals during the third quarter worth about $142,000. Finally, Raymond James Financial Services Advisors Inc. bought a new position in Olema Pharmaceuticals during the third quarter worth about $164,000. 91.78% of the stock is currently owned by institutional investors.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.